Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 1.08
MDSO's Cash to Debt is ranked higher than
56% of the 2118 Companies
in the Global Health Information Services industry.

( Industry Median: 4.93 vs. MDSO: 1.08 )
MDSO' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 1.08

Equity to Asset 0.42
MDSO's Equity to Asset is ranked higher than
53% of the 2048 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. MDSO: 0.42 )
MDSO' s 10-Year Equity to Asset Range
Min: -1.75   Max: 0.67
Current: 0.42

-1.75
0.67
Interest Coverage 4.03
MDSO's Interest Coverage is ranked lower than
58% of the 1326 Companies
in the Global Health Information Services industry.

( Industry Median: 1176.93 vs. MDSO: 4.03 )
MDSO' s 10-Year Interest Coverage Range
Min: 4.03   Max: 9999.99
Current: 4.03

4.03
9999.99
F-Score: 5
Z-Score: 5.75
M-Score: -2.31
WACC vs ROIC
12.03%
3.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 2.96
MDSO's Operating margin (%) is ranked higher than
73% of the 2100 Companies
in the Global Health Information Services industry.

( Industry Median: 5.37 vs. MDSO: 2.96 )
MDSO' s 10-Year Operating margin (%) Range
Min: -36.17   Max: 14
Current: 2.96

-36.17
14
Net-margin (%) 0.38
MDSO's Net-margin (%) is ranked higher than
64% of the 2100 Companies
in the Global Health Information Services industry.

( Industry Median: 3.67 vs. MDSO: 0.38 )
MDSO' s 10-Year Net-margin (%) Range
Min: -52.41   Max: 21.36
Current: 0.38

-52.41
21.36
ROE (%) 0.53
MDSO's ROE (%) is ranked higher than
63% of the 2033 Companies
in the Global Health Information Services industry.

( Industry Median: 6.20 vs. MDSO: 0.53 )
MDSO' s 10-Year ROE (%) Range
Min: 9.06   Max: 63.95
Current: 0.53

9.06
63.95
ROA (%) 0.22
MDSO's ROA (%) is ranked higher than
63% of the 2126 Companies
in the Global Health Information Services industry.

( Industry Median: 3.37 vs. MDSO: 0.22 )
MDSO' s 10-Year ROA (%) Range
Min: -106.4   Max: 22.66
Current: 0.22

-106.4
22.66
ROC (Joel Greenblatt) (%) 24.99
MDSO's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 2105 Companies
in the Global Health Information Services industry.

( Industry Median: 29.03 vs. MDSO: 24.99 )
MDSO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -324.06   Max: 274.82
Current: 24.99

-324.06
274.82
Revenue Growth (3Y)(%) 14.00
MDSO's Revenue Growth (3Y)(%) is ranked higher than
85% of the 1666 Companies
in the Global Health Information Services industry.

( Industry Median: 5.60 vs. MDSO: 14.00 )
MDSO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.7   Max: 14
Current: 14

-21.7
14
EBITDA Growth (3Y)(%) -5.60
MDSO's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 1378 Companies
in the Global Health Information Services industry.

( Industry Median: 7.20 vs. MDSO: -5.60 )
MDSO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 14.7
Current: -5.6

0
14.7
» MDSO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MDSO Guru Trades in Q1 2014

Steven Cohen 102,820 sh (New)
Ron Baron 518,040 sh (+328.13%)
Columbia Wanger 662,500 sh (+49.55%)
Jim Simons 80,669 sh (+34.24%)
Chuck Royce 40,000 sh (-4.08%)
» More
Q2 2014

MDSO Guru Trades in Q2 2014

Frank Sands 4,720,008 sh (New)
George Soros 126,666 sh (New)
Columbia Wanger 1,360,500 sh (+105.36%)
Steven Cohen 47,400 sh (unchged)
Chuck Royce 40,000 sh (unchged)
Jim Simons Sold Out
Ron Baron 230,635 sh (-55.48%)
» More
Q3 2014

MDSO Guru Trades in Q3 2014

Columbia Wanger 1,793,500 sh (+31.83%)
Frank Sands 4,866,217 sh (+3.1%)
Chuck Royce 40,000 sh (unchged)
Steven Cohen Sold Out
Ron Baron 193,346 sh (-16.17%)
George Soros 6,666 sh (-94.74%)
» More
Q4 2014

MDSO Guru Trades in Q4 2014

Jim Simons 5,494 sh (New)
Columbia Wanger 1,999,800 sh (+11.5%)
Frank Sands 5,126,077 sh (+5.34%)
Chuck Royce 40,000 sh (unchged)
George Soros Sold Out
Ron Baron 189,579 sh (-1.95%)
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-12-31 Sold Out $39.73 - $47.75 $ 48.1111%0
George Soros 2014-09-30 Reduce -94.74%0.04%$38.61 - $49.49 $ 48.118%6666
Frank Sands 2014-06-30 New Buy0.51%$33.98 - $58.27 $ 48.1116%4720008
Ron Baron 2014-06-30 Reduce -55.48%0.06%$33.98 - $58.27 $ 48.1116%230635
George Soros 2014-06-30 New Buy0.04%$33.98 - $58.27 $ 48.1116%126666
Ron Baron 2014-03-31 Add 328.13%0.08%$51.84 - $67.54 $ 48.11-21%518040
Ron Baron 2013-12-31 New Buy0.03%$43.03 - $61.755 $ 48.11-13%121000
Mariko Gordon 2013-12-31 Sold Out 0.02%$43.03 - $61.755 $ 48.11-13%0
Mariko Gordon 2013-09-30 New Buy0.02%$36.86 - $50.41 $ 48.119%3640
Joel Greenblatt 2012-12-31 Sold Out 0.04%$18.69 - $21.43 $ 48.11142%0
Joel Greenblatt 2012-06-30 Reduce -51.69%0.04%$12.28 - $16.34 $ 48.11250%16667
Joel Greenblatt 2012-03-31 Reduce -27.73%0.04%$9.31 - $13.83 $ 48.11366%34499
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2405.50
MDSO's P/E(ttm) is ranked higher than
64% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 56.70 vs. MDSO: 2405.50 )
MDSO' s 10-Year P/E(ttm) Range
Min: 11.44   Max: 2448.5
Current: 2405.5

11.44
2448.5
Forward P/E 43.67
MDSO's Forward P/E is ranked higher than
82% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. MDSO: 43.67 )
N/A
PE(NRI) 2405.50
MDSO's PE(NRI) is ranked higher than
64% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 59.00 vs. MDSO: 2405.50 )
MDSO' s 10-Year PE(NRI) Range
Min: 11.53   Max: 2448.5
Current: 2405.5

11.53
2448.5
P/B 10.46
MDSO's P/B is ranked higher than
52% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 3.32 vs. MDSO: 10.46 )
MDSO' s 10-Year P/B Range
Min: 4.53   Max: 28.83
Current: 10.46

4.53
28.83
P/S 8.18
MDSO's P/S is ranked higher than
53% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 2.67 vs. MDSO: 8.18 )
MDSO' s 10-Year P/S Range
Min: 1.31   Max: 12.62
Current: 8.18

1.31
12.62
PFCF 77.60
MDSO's PFCF is ranked higher than
73% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 102.32 vs. MDSO: 77.60 )
MDSO' s 10-Year PFCF Range
Min: 12.91   Max: 276.85
Current: 77.6

12.91
276.85
POCF 44.14
MDSO's POCF is ranked higher than
68% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 28.43 vs. MDSO: 44.14 )
MDSO' s 10-Year POCF Range
Min: 10.42   Max: 133.3
Current: 44.14

10.42
133.3
EV-to-EBIT 273.40
MDSO's EV-to-EBIT is ranked higher than
63% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 36.34 vs. MDSO: 273.40 )
MDSO' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 381.8
Current: 273.4

8.8
381.8
Shiller P/E 153.70
MDSO's Shiller P/E is ranked higher than
78% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 0.00 vs. MDSO: 153.70 )
MDSO' s 10-Year Shiller P/E Range
Min: 126.29   Max: 6000
Current: 153.7

126.29
6000
Current Ratio 3.95
MDSO's Current Ratio is ranked higher than
88% of the 2080 Companies
in the Global Health Information Services industry.

( Industry Median: 1.88 vs. MDSO: 3.95 )
MDSO' s 10-Year Current Ratio Range
Min: 0.44   Max: 5.35
Current: 3.95

0.44
5.35
Quick Ratio 3.95
MDSO's Quick Ratio is ranked higher than
88% of the 2080 Companies
in the Global Health Information Services industry.

( Industry Median: 1.77 vs. MDSO: 3.95 )
MDSO' s 10-Year Quick Ratio Range
Min: 0.44   Max: 5.35
Current: 3.95

0.44
5.35
Days Sales Outstanding 57.98
MDSO's Days Sales Outstanding is ranked higher than
74% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 84.50 vs. MDSO: 57.98 )
MDSO' s 10-Year Days Sales Outstanding Range
Min: 45.45   Max: 90.9
Current: 57.98

45.45
90.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.16
MDSO's Price/Tangible Book is ranked higher than
64% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 8.39 vs. MDSO: 11.16 )
MDSO' s 10-Year Price/Tangible Book Range
Min: 6.32   Max: 151.5
Current: 11.16

6.32
151.5
Price/DCF (Projected) 6.80
MDSO's Price/DCF (Projected) is ranked higher than
74% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 7.56 vs. MDSO: 6.80 )
MDSO' s 10-Year Price/DCF (Projected) Range
Min: 4.85   Max: 10.1
Current: 6.8

4.85
10.1
Price/Median PS Value 2.22
MDSO's Price/Median PS Value is ranked higher than
55% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 1.28 vs. MDSO: 2.22 )
MDSO' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.21
Current: 2.22

0.36
3.21
Price/Graham Number 32.51
MDSO's Price/Graham Number is ranked higher than
69% of the 2303 Companies
in the Global Health Information Services industry.

( Industry Median: 16.38 vs. MDSO: 32.51 )
MDSO' s 10-Year Price/Graham Number Range
Min: 1.91   Max: 29.93
Current: 32.51

1.91
29.93
Earnings Yield (Greenblatt) 0.40
MDSO's Earnings Yield (Greenblatt) is ranked higher than
61% of the 2102 Companies
in the Global Health Information Services industry.

( Industry Median: 3.40 vs. MDSO: 0.40 )
MDSO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 11.3
Current: 0.4

0.3
11.3
Forward Rate of Return (Yacktman) -0.91
MDSO's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 1125 Companies
in the Global Health Information Services industry.

( Industry Median: 12.92 vs. MDSO: -0.91 )
MDSO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 21.2
Current: -0.91

-0.9
21.2

Business Description

Industry: Application Software » Health Information Services
Compare: » details
Traded in other countries:2M9.Germany,
Medidata Solutions, Inc., was incorporated in June 1999and reincorporated in the State of Delaware in May 2000. The Company is a provider of cloud-based solutions for clinical research in life sciences, designed to transform clinical development and increase the value of the customers' research investments. Medidata's solutions are designed to address the underlying requirements of clinical development, rather than just its current processes, to maximize the value of the overall research process. Its cloud-based solutions, metrics and services allow users to accurately and efficiently design clinical trials; manage and monitor ongoing trial activities; develop and administer trial budgets; capture, manage and report clinical trial data; plan and execute randomized subject allocation methodologies; manage and allocate clinical trial supplies; and view, track, and evaluate trial progress through easy-to-use, Internet-enabled platforms. The Company compete with firms such as Oracle, Perceptive Informatics and others offering products and services that compete with one or more of the solutions. It competes on the basis of several factors, including, breadth and depth of solution offerings; platform capabilities, including interoperability; ease of use of solutions and rates of user adoption; solution functionality and flexibility; analytics and benchmarking; speed and performance required to enable customers to access clinical trial data in real-time; product reliability and scalability; infrastructure accessibility and security; regulatory compliance; financial stability; commercial and technology partnerships; depth of expertise and quality of professional services and customer support on a global basis; and sales and marketing capabilities, including the ability to create and communicate operational value. The Company has registered trademarks and service marks in the United States and abroad, and filed applications for the registration of additional trademarks and service marks. The principal trademarks are "Medidata," "Medidata Clinical Cloud," "Medidata Patient Cloud," "Medidata CRO Contractor," "Medidata Designer," "Medidata Grants Manager," "Medidata Rave," "Medidata Balance," "Medidata Coder," and "Medidata Insights." It also holds several domain names, including the domain names "mdsol.com" and "medidatasolutions.com". The use of Company's software products, services and hosted solutions by customers engaged in clinical trials must be done in a manner that is compliant with a complex array of United States federal and state laws and regulations, including regulation by the Food and Drug Administration, as well as regulations and guidance issued by foreign governments and international non-governmental organizations.
» More Articles for MDSO

Headlines

Articles On GuruFocus.com
Medidata: SaaS Business Model Leveraging Growth Of The Company Oct 23 2014 
Frank Sands Adds 5 New Stocks Aug 14 2014 
Medidata Solutions: Benefit from Growing Cloud Applications with This Stock May 27 2014 
Medidata Solutions : A SAAS Provider For Your Portfolio Mar 23 2014 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,667 Shares Mar 08 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,000 Shares Mar 03 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 13,667 Shares Feb 07 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 3,000 Shares Feb 03 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 13,667 Shares Jan 10 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 3,000 Shares Jan 05 2011 

More From Other Websites
Medidata's Cloud and Mobile Technology Selected to Drive Collaborative, 10-Year Research in... Feb 23 2015
Medidata’s Cloud and Mobile Technology Selected to Drive Collaborative, 10-Year Research in... Feb 23 2015
MEDIDATA SOLUTIONS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 20 2015
Medidata to Present at Morgan Stanley Technology, Media & Telecom Conference Feb 17 2015
Medidata to Present at Morgan Stanley Technology, Media & Telecom Conference Feb 17 2015
TWi Biotechnology Selects Medidata's Cloud-Based Platform to Advance Cutting-Edge Clinical... Feb 11 2015
TWi Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Cutting-Edge Clinical... Feb 11 2015
Thermo Fisher's Q4 Gains on Life Technologies Integration - Analyst Blog Feb 11 2015
Cerner Q4 Earnings & Revenues Beat Estimates, Up Y/Y - Analyst Blog Feb 11 2015
Merge, ICT Health Tie Up for Imaging Solutions in IMEA Region - Analyst Blog Feb 10 2015
CVS Health Earnings in Line, Revenues Beat Estimates in Q4 - Analyst Blog Feb 10 2015
Omnicell Posts Solid Q4, Positive on 3-Legged Strategies - Analyst Blog Feb 10 2015
Medidata Teams Up with Garmin to Optimize Clinical Trials through Mobile Health Technology Feb 09 2015
Medidata Teams Up with Garmin to Optimize Clinical Trials through Mobile Health Technology Feb 09 2015
athenahealth Tops Q4 Earnings & Revenues; '15 View Revised - Analyst Blog Feb 06 2015
Medidata Solutions Inc Earnings Call scheduled for 8:00 am ET today Feb 05 2015
Q4 2014 Medidata Solutions Inc Earnings Release - Before Market Open Feb 05 2015
Medidata tops 4Q profit forecasts Feb 05 2015
Medidata tops 4Q profit forecasts Feb 05 2015
Medidata Reports Record Full Year and Fourth Quarter 2014 Revenues Feb 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK